9:16 AM ET
8-K
Clinical Trial Data
Gain Therapeutics Clinical Trial Data
Gain Therapeutics presented 12-month open-label extension data from its Phase 1b study of rexaceract, showing stabilization of MDS-UPDRS motor scores in Parkinson’s disease patients. The data suggests disease-modifying potential as patients showed no clinically meaningful progression of motor symptoms over the one-year period. The company plans to submit a Phase 2 protocol to the FDA and initiate a Phase 2 trial in Q1 2027.
- Term
- 12 months